Oncotype DX Colon Recurrence Score

Publications

Publications: Oncotype DX Colon Recurrence Score

Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer.
Alberts SR, Yu TM, Behrens RJ, et al.
PharmacoEconomics. 2014. 1.

Prospective Multicenter Study of the Impact of Oncotype DX Colon Cancer Assay Results on Treatment Recommendations in Stage II Colon Cancer Patients.
Srivastava G, Renfro LA, Behrens RJ, et al.
Oncologist. 2014. 10.1634: 1.

Validation of the 12-gene colon cancer Recurrence Score in NSABP C-07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5-FU/LV and 5-FU/LV+ oxaliplatin.
Yothers G, O’Connell M, Lee M, et al.
J Clin Oncol. 2013. 31(36): 4512-9.

Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581.
Venook A.P., Niedzwiecki D. Lopatin M., et al.
J Clin Oncol. 2013. 31(14): 1775-1781.

Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer.
Gray RG, Quirke P, Handley K, et al.
J Clin Oncol. 2011. 29(35): 4611-9.

Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with Stage II colon cancer.
Cartwright T, Chao C, Lee M, et al.
Curr Med Res Opin. 2014. 30(2): 321-328.

A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.
Hornberger J, Lyman GH, Chien R, Meropol NJ.
Value Health. 2012. 15(8): 1014-21.

Relationship between tumor gene expression and recurrence in four independent studies of stage II/III colon cancer patients treated with surgery alone and surgery plus adjuvant fluorouracil plus leucovorin.
O’Connell MJ, Lavery I, Yothers G, et al.
J Clin Oncol. 2010. 28(5): 3904-7.</br.>

Translating tumor biology into personalized treatment planning: Analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
Clark-Langone et al.
BMC Cancer. 2010. 10: 691.

Biomarker discovery for colon cancer using a 761 gene RT-PCR assay.
Clark-Langone KM, Wu JY, Sangli C, et al.
BMC Genomics. 2007. 8: 279-97.

Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers.
Simon R
J Clin Oncol. 2005.

Platform Technology

Measurement of Gene Expression in Archival Paraffin-Embedded Tissues.
Cronin M, Pho M, Dutta D, et al
Am J Pathol. 2004.

Biomarker discovery for colon cancer using a 761 gene RT-PCR assay.
Clark-Langone KM, Wu JY, Sangli C, et al
BMC Genomics. 8(279): 1471-2164-8-279.

Clinical Validation:
QUASARb

The first validation study for the Colon Recurrence Score analyzed samples from the Quick and Simple and Reliable (QUASAR) Trial.

Read Full Text

Clinical Validation:
NSABP C-07b

A second confirmatory study in a subset of patients from the National Surgical Adjuvant Breast and Bowel Project (NASPB).

Read Full Text

Clinical Validation:
CALGB 9581c

A confirmatory validation study analyzed samples from the Cancer and Leukemia Group B (CALBG) 9581 study.

Read Full Text

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™